Great post! You are right on the money my friend. I don't know what exactly people are looking for or want for this company to be successful (at this point in the journey to making progress with future commercialization of their drug development programs and products...to reach commercialization).
Bottom line: They are making significant progress with reaching their stated goals and objectives. Its very transparent in Gerlads communication and update.
I fully agree that AMBS does a good job of keeping us updated and fully agree we will be rewarded for holding. However the financing options are the same options every biotech has and haven't change in the last several months. It is good news they have a partnership in BD to move the diagnostic forward which will save the company money. I don't want fluff PRs every week I was hopeful this PR would have online more substantial funding.
Also like I said if this drifts lower I will add more shares. The company is not a death bed for financing BUT can you tell me where the are currently getting money to cover their $250k per month burn rate?
Such words are typical CEO talk, yes they are waiting for a white knight, without one AMBS is doomed and vultures will be waiting to tear her up in BK. Gerald bought MANF in BK for nothing sad but the same fate awaits him .He has out played himself but he will get out clean with some profit from the penny stock holders. To bad there is no bright future here the death march has began
Other small cap biotechs give clear concise numbers pertaining to available funds on hand to carry through to a specific date, including clear current burn rate and projected future burn rate in 10Q and 10K. They also give a clear listing of competition in 10K. An example would be one of Rubenfield's other Board associated companies which started working with ALS and then switched to a cancer focus. Upcoming AMBS 10Q will shed light on the truth of the matter.
News 
Market Data 
Discover 
AI
